AML ASH 22
Matthew Davids, MD, MMSc, discusses ZUMA-8 results during the 2022 Annual American Society of Hematology Meeting.
Hispanics with AML had improved survival compared to non-Hispanic Blacks or non-Hispanic whites in a non-transplant setting.
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
A whole-genome transcriptome sequencing study of hairy cell leukemia revealed a high degree of genomic complexity.
Maintenance therapy with venetoclax plus azacitidine may be a good option after transplant in high-risk acute leukemia.
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Triplet of Decitabine, Venetoclax, and Ponatinib Shows Promise in Myeloid Blast Phase CML or Ph+ AML
Decitabine, venetoclax, and ponatinib was well tolerated in patients with CML in myeloid blast phase or Ph-positive AML. 
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
The use of venetoclax-containing therapy effectively bridged patients with relapsed or refractory AML.
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.